ID   TGFR1_HUMAN             Reviewed;         503 AA.
AC   P36897; Q6IR47; Q706C0; Q706C1;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   12-OCT-2022, entry version 237.
DE   RecName: Full=TGF-beta receptor type-1;
DE            Short=TGFR-1;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin A receptor type II-like protein kinase of 53kD;
DE   AltName: Full=Activin receptor-like kinase 5;
DE            Short=ALK-5;
DE            Short=ALK5;
DE   AltName: Full=Serine/threonine-protein kinase receptor R4;
DE            Short=SKR4;
DE   AltName: Full=TGF-beta type I receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type I;
DE            Short=TGF-beta receptor type I;
DE            Short=TbetaR-I;
DE   Flags: Precursor;
GN   Name=TGFBR1; Synonyms=ALK5, SKR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8242743; DOI=10.1016/0092-8674(93)90489-d;
RA   Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P., Heldin C.-H.,
RA   Miyazono K.;
RT   "Cloning of a TGF beta type I receptor that forms a heteromeric complex
RT   with the TGF beta type II receptor.";
RL   Cell 75:681-692(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9417915; DOI=10.1006/geno.1997.5023;
RA   Vellucci V.F., Reiss M.;
RT   "Cloning and genomic organization of the human transforming growth factor-
RT   beta type I receptor gene.";
RL   Genomics 46:278-283(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Lynch M.A., Song H., DeGroff V.L., Alam K.Y., Adams E.M., Weghorst C.M.;
RT   "The genomic structure of the gene encoding the human transforming growth
RT   factor beta type I receptor.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 34-40, SIGNAL SEQUENCE CLEAVAGE SITE, GLYCOSYLATION,
RP   CHARACTERIZATION OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL, AND VARIANT
RP   TGFBR1*10A ALA-26 INS.
RX   PubMed=9661882;
RA   Pasche B., Luo Y., Rao P.H., Nimer S.D., Dmitrovsky E., Caron P.,
RA   Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J.M.,
RA   Murty V.V., Massague J.;
RT   "Type I transforming growth factor beta receptor maps to 9q22 and exhibits
RT   a polymorphism and a rare variant within a polyalanine tract.";
RL   Cancer Res. 58:2727-2732(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   61-155 (ISOFORM 1), AND ALTERNATIVE SPLICING.
RC   TISSUE=Prostate;
RX   PubMed=17845732; DOI=10.1186/1471-2164-8-318;
RA   Konrad L., Scheiber J.A., Volck-Badouin E., Keilani M.M., Laible L.,
RA   Brandt H., Schmidt A., Aumuller G., Hofmann R.;
RT   "Alternative splicing of TGF-betas and their high-affinity receptors T beta
RT   RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human
RT   prostatic cells.";
RL   BMC Genomics 8:318-318(2007).
RN   [9]
RP   SEQUENCE REVISION (ISOFORM 1).
RA   Konrad L.;
RL   Submitted (MAR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT THR-185; THR-186; SER-187; SER-189 AND SER-191
RP   BY TGFBR2, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF
RP   185-THR-THR-186; SER-187; SER-189; SER-191; THR-200 AND THR-204.
RX   PubMed=7774578; DOI=10.1002/j.1460-2075.1995.tb07214.x;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF SMAD2.
RX   PubMed=8752209; DOI=10.1016/s0092-8674(00)80128-2;
RA   Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H.,
RA   Tsui L.-C., Bapat B., Gallinger S., Andrulis I.L., Thomsen G.H.,
RA   Wrana J.L., Attisano L.;
RT   "MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein
RT   that is functionally mutated in colorectal carcinoma.";
RL   Cell 86:543-552(1996).
RN   [12]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND FUNCTION
RP   IN TRANSCRIPTION REGULATION.
RX   PubMed=8980228; DOI=10.1016/s0092-8674(00)81817-6;
RA   Macias-Silva M., Abdollah S., Hoodless P.A., Pirone R., Attisano L.,
RA   Wrana J.L.;
RT   "MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is
RT   required for nuclear accumulation and signaling.";
RL   Cell 87:1215-1224(1996).
RN   [13]
RP   INTERACTION WITH FKBP1A, ACTIVITY REGULATION, AND MUTAGENESIS OF LEU-193
RP   AND PRO-194.
RX   PubMed=9233797; DOI=10.1093/emboj/16.13.3866;
RA   Chen Y.G., Liu F., Massague J.;
RT   "Mechanism of TGFbeta receptor inhibition by FKBP12.";
RL   EMBO J. 16:3866-3876(1997).
RN   [14]
RP   INTERACTION WITH SMAD3.
RX   PubMed=9311995; DOI=10.1093/emboj/16.17.5353;
RA   Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E.,
RA   Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.;
RT   "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.";
RL   EMBO J. 16:5353-5362(1997).
RN   [15]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND FUNCTION
RP   IN TRANSCRIPTION REGULATION.
RX   PubMed=9346908; DOI=10.1074/jbc.272.44.27678;
RA   Abdollah S., Macias-Silva M., Tsukazaki T., Hayashi H., Attisano L.,
RA   Wrana J.L.;
RT   "TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for
RT   Smad2-Smad4 complex formation and signaling.";
RL   J. Biol. Chem. 272:27678-27685(1997).
RN   [16]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.";
RL   Cell 95:779-791(1998).
RN   [17]
RP   HOMODIMERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9472030; DOI=10.1083/jcb.140.4.767;
RA   Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.;
RT   "Oligomeric structure of type I and type II transforming growth factor beta
RT   receptors: homodimers form in the ER and persist at the plasma membrane.";
RL   J. Cell Biol. 140:767-777(1998).
RN   [18]
RP   INTERACTION WITH SMAD7 AND SMURF2, AND PROTEASOMAL AND LYSOSOMAL
RP   DEGRADATION.
RX   PubMed=11163210; DOI=10.1016/s1097-2765(00)00134-9;
RA   Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H.,
RA   Wrana J.L.;
RT   "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-
RT   beta receptor for degradation.";
RL   Mol. Cell 6:1365-1375(2000).
RN   [19]
RP   INTERACTION WITH SMAD7 AND SMURF1, AND PROTEASOMAL DEGRADATION.
RX   PubMed=11278251; DOI=10.1074/jbc.c100008200;
RA   Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T.,
RA   Miyazono K.;
RT   "Smurf1 interacts with transforming growth factor-beta type I receptor
RT   through Smad7 and induces receptor degradation.";
RL   J. Biol. Chem. 276:12477-12480(2001).
RN   [20]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S.,
RA   McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [21]
RP   INTERACTION WITH NEDD4L, AND UBIQUITINATION.
RX   PubMed=15496141; DOI=10.1042/bj20040738;
RA   Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K., Miyazono K.,
RA   Imamura T.;
RT   "NEDD4-2 (neural precursor cell expressed, developmentally down-regulated
RT   4-2) negatively regulates TGF-beta (transforming growth factor-beta)
RT   signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta
RT   type I receptor.";
RL   Biochem. J. 386:461-470(2005).
RN   [22]
RP   FUNCTION IN EPITHELIAL TO MESENCHYMAL TRANSITION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH PARD6A, AND FUNCTION IN PHOSPHORYLATION OF PARD6A.
RX   PubMed=15761148; DOI=10.1126/science.1105718;
RA   Ozdamar B., Bose R., Barrios-Rodiles M., Wang H.R., Zhang Y., Wrana J.L.;
RT   "Regulation of the polarity protein Par6 by TGFbeta receptors controls
RT   epithelial cell plasticity.";
RL   Science 307:1603-1609(2005).
RN   [23]
RP   FUNCTION IN CELLULAR GROWTH INHIBITION, AND INTERACTION WITH CD109.
RX   PubMed=16754747; DOI=10.1096/fj.05-5229fje;
RA   Finnson K.W., Tam B.Y.Y., Liu K., Marcoux A., Lepage P., Roy S.,
RA   Bizet A.A., Philip A.;
RT   "Identification of CD109 as part of the TGF-beta receptor system in human
RT   keratinocytes.";
RL   FASEB J. 20:1525-1527(2006).
RN   [24]
RP   INTERACTION WITH RBPMS.
RX   PubMed=17099224; DOI=10.1093/nar/gkl914;
RA   Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H.,
RA   Ye Q.;
RT   "Potentiation of Smad-mediated transcriptional activation by the RNA-
RT   binding protein RBPMS.";
RL   Nucleic Acids Res. 34:6314-6326(2006).
RN   [25]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH TRAF6 AND MAP3K7.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor
RT   kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [26]
RP   REVIEW ON PROCESSES REGULATED BY THE TGF-BETA CYTOKINES.
RX   PubMed=9759503; DOI=10.1146/annurev.biochem.67.1.753;
RA   Massague J.;
RT   "TGF-beta signal transduction.";
RL   Annu. Rev. Biochem. 67:753-791(1998).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP15.
RX   PubMed=22344298; DOI=10.1038/nm.2619;
RA   Eichhorn P.J., Rodon L., Gonzalez-Junca A., Dirac A., Gili M.,
RA   Martinez-Saez E., Aura C., Barba I., Peg V., Prat A., Cuartas I.,
RA   Jimenez J., Garcia-Dorado D., Sahuquillo J., Bernards R., Baselga J.,
RA   Seoane J.;
RT   "USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the
RT   activation of TGF-beta signaling in glioblastoma.";
RL   Nat. Med. 18:429-435(2012).
RN   [29]
RP   INTERACTION WITH SDCBP AND CAV1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=25893292; DOI=10.1038/onc.2015.100;
RA   Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.;
RT   "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial-
RT   to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I
RT   receptor internalization.";
RL   Oncogene 35:389-401(2016).
RN   [30]
RP   INTERACTION WITH APPL1.
RX   PubMed=26583432; DOI=10.18632/oncotarget.6346;
RA   Song J., Mu Y., Li C., Bergh A., Miaczynska M., Heldin C.H., Landstroem M.;
RT   "APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta
RT   type I receptor intracellular domain.";
RL   Oncotarget 7:279-292(2016).
RN   [31]
RP   3D-STRUCTURE MODELING OF 34-114.
RX   PubMed=8521960; DOI=10.1016/0014-5793(95)01239-7;
RA   Jokiranta T.S., Tissari J., Teleman O., Meri S.;
RT   "Extracellular domain of type I receptor for transforming growth factor-
RT   beta: molecular modelling using protectin (CD59) as a template.";
RL   FEBS Lett. 376:31-36(1995).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 162-503 IN COMPLEX WITH FKBP1A.
RX   PubMed=10025408; DOI=10.1016/s0092-8674(00)80555-3;
RA   Huse M., Chen Y.-G., Massague J., Kuriyan J.;
RT   "Crystal structure of the cytoplasmic domain of the type I TGF beta
RT   receptor in complex with FKBP12.";
RL   Cell 96:425-436(1999).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 162-503, PHOSPHORYLATION, AND
RP   INTERACTION WITH SMAD2 AND FKBP1A.
RX   PubMed=11583628; DOI=10.1016/s1097-2765(01)00332-x;
RA   Huse M., Muir T.W., Xu L., Chen Y.-G., Kuriyan J., Massague J.;
RT   "The TGF beta receptor activation process: an inhibitor- to substrate-
RT   binding switch.";
RL   Mol. Cell 8:671-682(2001).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 175-500 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=15177479; DOI=10.1016/j.bmcl.2004.04.007;
RA   Sawyer J.S., Beight D.W., Britt K.S., Anderson B.D., Campbell R.M.,
RA   Goodson T. Jr., Herron D.K., Li H.-Y., McMillen W.T., Mort N., Parsons S.,
RA   Smith E.C.R., Wagner J.R., Yan L., Zhang F., Yingling J.M.;
RT   "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-
RT   dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth
RT   factor-beta type I receptor kinase domain.";
RL   Bioorg. Med. Chem. Lett. 14:3581-3584(2004).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 201-503 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=15317461; DOI=10.1021/jm0400247;
RA   Gellibert F., Woolven J., Fouchet M.-H., Mathews N., Goodland H.,
RA   Lovegrove V., Laroze A., Nguyen V.-L., Sautet S., Wang R., Janson C.,
RA   Smith W., Krysa G., Boullay V., De Gouville A.-C., Huet S., Hartley D.;
RT   "Identification of 1,5-naphthyridine derivatives as a novel series of
RT   potent and selective TGF-beta type I receptor inhibitors.";
RL   J. Med. Chem. 47:4494-4506(2004).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 33-111 IN COMPLEX WITH TGFBR2 AND
RP   TGFB3, AND DISULFIDE BONDS.
RX   PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039;
RA   Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P.,
RA   Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.;
RT   "Cooperative assembly of TGF-beta superfamily signaling complexes is
RT   mediated by two disparate mechanisms and distinct modes of receptor
RT   binding.";
RL   Mol. Cell 29:157-168(2008).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 31-115 IN COMPLEX WITH TGFBR2 AND
RP   TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS.
RX   PubMed=20207738; DOI=10.1074/jbc.m109.079921;
RA   Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.;
RT   "Ternary complex of transforming growth factor-beta1 reveals isoform-
RT   specific ligand recognition and receptor recruitment in the superfamily.";
RL   J. Biol. Chem. 285:14806-14814(2010).
RN   [38]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN CANCER RISK.
RX   PubMed=12947057; DOI=10.1200/jco.2003.11.524;
RA   Kaklamani V.G., Hou N., Bian Y., Reich J., Offit K., Michel L.S.,
RA   Rubinstein W.S., Rademaker A., Pasche B.;
RT   "TGFBR1*6A and cancer risk: a meta-analysis of seven case-control
RT   studies.";
RL   J. Clin. Oncol. 21:3236-3243(2003).
RN   [39]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15385056; DOI=10.1186/1471-2156-5-28;
RA   Kaklamani V.G., Baddi L., Rosman D., Liu J., Ellis N., Oddoux C.,
RA   Ostrer H., Chen Y., Ahsan H., Offit K., Pasche B.;
RT   "No major association between TGFBR1*6A and prostate cancer.";
RL   BMC Genet. 5:28-28(2004).
RN   [40]
RP   VARIANTS LDS1 ILE-200; ARG-318; GLY-400 AND PRO-487.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B., De Paepe A.M.,
RA   Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive and
RT   skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [41]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15505640; DOI=10.1038/sj.pcan.4500765;
RA   Suarez B.K., Pal P., Jin C.H., Kaushal R., Sun G., Jin L., Pasche B.,
RA   Deka R., Catalona W.J.;
RT   "TGFBR1(*)6A is not associated with prostate cancer in men of European
RT   ancestry.";
RL   Prostate Cancer Prostatic Dis. 8:50-53(2005).
RN   [42]
RP   VARIANT LDS1 LEU-241.
RX   PubMed=16596670; DOI=10.1002/ajmg.a.31202;
RA   Ades L.C., Sullivan K., Biggin A., Haan E.A., Brett M., Holman K.J.,
RA   Dixon J., Robertson S., Holmes A.D., Rogers J., Bennetts B.;
RT   "FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders
RT   revisited.";
RL   Am. J. Med. Genet. A 140:1047-1058(2006).
RN   [43]
RP   VARIANTS LDS1 LEU-241 AND GLN-487, AND VARIANT HIS-267.
RX   PubMed=16791849; DOI=10.1002/humu.20353;
RA   Matyas G., Arnold E., Carrel T., Baumgartner D., Boileau C., Berger W.,
RA   Steinmann B.;
RT   "Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations
RT   in Marfan syndrome-related disorders.";
RL   Hum. Mutat. 27:760-769(2006).
RN   [44]
RP   VARIANTS LDS1 GLU-232; TRP-487; PRO-487 AND GLN-487.
RX   PubMed=16928994; DOI=10.1056/nejmoa055695;
RA   Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H., Pannu H.,
RA   De Backer J.F., Oswald G.L., Symoens S., Manouvrier S., Roberts A.E.,
RA   Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M., Coucke P.J.,
RA   Cameron D.E., Braverman A.C., Byers P.H., De Paepe A.M., Dietz H.C.;
RT   "Aneurysm syndromes caused by mutations in the TGF-beta receptor.";
RL   N. Engl. J. Med. 355:788-798(2006).
RN   [45]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-153 AND CYS-291.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [46]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-139.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [47]
RP   VARIANT LDS1 GLY-351.
RX   PubMed=19883511; DOI=10.1186/1750-1172-4-24;
RA   Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R.,
RA   Calzavara-Pinton P.G., Barlati S., Colombi M.;
RT   "Loeys-Dietz syndrome type I and type II: clinical findings and novel
RT   mutations in two Italian patients.";
RL   Orphanet J. Rare Dis. 4:24-24(2009).
RN   [48]
RP   VARIANTS LDS1 TYR-266; ARG-375 AND GLN-487.
RX   PubMed=22113417; DOI=10.1038/jhg.2011.130;
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RT   "Clinical features and genetic analysis of Korean patients with Loeys-Dietz
RT   syndrome.";
RL   J. Hum. Genet. 57:52-56(2012).
RN   [49]
RP   ERRATUM OF PUBMED:22113417.
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RL   J. Hum. Genet. 57:398-398(2012).
RN   [50]
RP   VARIANTS MSSE TYR-41; SER-45; ARG-52 AND LEU-83.
RX   PubMed=21358634; DOI=10.1038/ng.780;
RA   Goudie D.R., D'Alessandro M., Merriman B., Lee H., Szeverenyi I., Avery S.,
RA   O'Connor B.D., Nelson S.F., Coats S.E., Stewart A., Christie L.,
RA   Pichert G., Friedel J., Hayes I., Burrows N., Whittaker S., Gerdes A.M.,
RA   Broesby-Olsen S., Ferguson-Smith M.A., Verma C., Lunny D.P., Reversade B.,
RA   Lane E.B.;
RT   "Multiple self-healing squamous epithelioma is caused by a disease-specific
RT   spectrum of mutations in TGFBR1.";
RL   Nat. Genet. 43:365-369(2011).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the TGF-
CC       beta type II serine/threonine kinase receptor, TGFBR2, the non-
CC       promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.
CC       Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to
CC       the cytoplasm and is thus regulating a plethora of physiological and
CC       pathological processes including cell cycle arrest in epithelial and
CC       hematopoietic cells, control of mesenchymal cell proliferation and
CC       differentiation, wound healing, extracellular matrix production,
CC       immunosuppression and carcinogenesis. The formation of the receptor
CC       complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound
CC       to the cytokine dimer results in the phosphorylation and the activation
CC       of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and interacts
CC       with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the
CC       nucleus where it modulates the transcription of the TGF-beta-regulated
CC       genes. This constitutes the canonical SMAD-dependent TGF-beta signaling
CC       cascade. Also involved in non-canonical, SMAD-independent TGF-beta
CC       signaling pathways. For instance, TGFBR1 induces TRAF6
CC       autoubiquitination which in turn results in MAP3K7 ubiquitination and
CC       activation to trigger apoptosis. Also regulates epithelial to
CC       mesenchymal transition through a SMAD-independent signaling pathway
CC       through PARD6A phosphorylation and activation.
CC       {ECO:0000269|PubMed:15761148, ECO:0000269|PubMed:16754747,
CC       ECO:0000269|PubMed:18758450, ECO:0000269|PubMed:7774578,
CC       ECO:0000269|PubMed:8752209, ECO:0000269|PubMed:8980228,
CC       ECO:0000269|PubMed:9346908}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Kept in an inactive conformation by FKBP1A
CC       preventing receptor activation in absence of ligand. CD109 is another
CC       inhibitor of the receptor. {ECO:0000269|PubMed:9233797}.
CC   -!- SUBUNIT: Homodimer; in the endoplasmic reticulum but also at the cell
CC       membrane. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric ligands
CC       assemble a functional receptor composed of two TGFBR1 and TGFBR2
CC       heterodimers to form a ligand-receptor heterohexamer. The respective
CC       affinity of TGBRB1 and TGFBR2 for the ligands may modulate the kinetics
CC       of assembly of the receptor and may explain the different biological
CC       activities of TGFB1, TGFB2 and TGFB3. Interacts with CD109; inhibits
CC       TGF-beta receptor activation in keratinocytes. Interacts with RBPMS.
CC       Interacts (unphosphorylated) with FKBP1A; prevents TGFBR1
CC       phosphorylation by TGFBR2 and stabilizes it in the inactive
CC       conformation. Interacts with SMAD2, SMAD3 and ZFYVE9; ZFYVE9 recruits
CC       SMAD2 and SMAD3 to the TGF-beta receptor. Interacts with TRAF6 and
CC       MAP3K7; induces MAP3K7 activation by TRAF6. Interacts with PARD6A;
CC       involved in TGF-beta induced epithelial to mesenchymal transition.
CC       Interacts with SMAD7, NEDD4L, SMURF1 and SMURF2; SMAD7 recruits NEDD4L,
CC       SMURF1 and SMURF2 to the TGF-beta receptor. Interacts with USP15 and
CC       VPS39. Interacts with SDCBP (via C-terminus) (PubMed:25893292)
CC       Interacts with CAV1 and this interaction is impaired in the presence of
CC       SDCBP (PubMed:25893292). Interacts with APPL1; interaction is TGF beta
CC       dependent; mediates trafficking of the TGFBR1 from the endosomes to the
CC       nucleus via microtubules in a TRAF6-dependent manner (PubMed:26583432).
CC       {ECO:0000269|PubMed:10025408, ECO:0000269|PubMed:11163210,
CC       ECO:0000269|PubMed:11278251, ECO:0000269|PubMed:11583628,
CC       ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:15177479,
CC       ECO:0000269|PubMed:15317461, ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:15761148, ECO:0000269|PubMed:16754747,
CC       ECO:0000269|PubMed:17099224, ECO:0000269|PubMed:18243111,
CC       ECO:0000269|PubMed:18758450, ECO:0000269|PubMed:20207738,
CC       ECO:0000269|PubMed:25893292, ECO:0000269|PubMed:26583432,
CC       ECO:0000269|PubMed:7774578, ECO:0000269|PubMed:8980228,
CC       ECO:0000269|PubMed:9233797, ECO:0000269|PubMed:9311995,
CC       ECO:0000269|PubMed:9346908, ECO:0000269|PubMed:9865696}.
CC   -!- INTERACTION:
CC       P36897; P62942: FKBP1A; NbExp=2; IntAct=EBI-1027557, EBI-1027571;
CC       P36897; P01137: TGFB1; NbExp=2; IntAct=EBI-1027557, EBI-779636;
CC       P36897; P63104: YWHAZ; NbExp=4; IntAct=EBI-1027557, EBI-347088;
CC       P36897; PRO_0000045599 [Q99IB8]; Xeno; NbExp=5; IntAct=EBI-1027557, EBI-6858501;
CC       P36897-1; P02750: LRG1; NbExp=6; IntAct=EBI-16065417, EBI-9083443;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25893292,
CC       ECO:0000269|PubMed:9472030}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:9472030}. Cell junction, tight junction
CC       {ECO:0000269|PubMed:15761148}. Cell surface
CC       {ECO:0000269|PubMed:25893292}. Membrane raft
CC       {ECO:0000269|PubMed:25893292}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P36897-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=P36897-2; Sequence=VSP_041326;
CC       Name=3;
CC         IsoId=P36897-3; Sequence=VSP_041327;
CC   -!- TISSUE SPECIFICITY: Found in all tissues examined, most abundant in
CC       placenta and least abundant in brain and heart. Expressed in a variety
CC       of cancer cell lines (PubMed:25893292). {ECO:0000269|PubMed:25893292}.
CC   -!- PTM: Phosphorylated at basal levels in the absence of ligand. Activated
CC       upon phosphorylation by TGFBR2, mainly in the GS domain.
CC       Phosphorylation in the GS domain abrogates FKBP1A-binding.
CC       {ECO:0000269|PubMed:11583628, ECO:0000269|PubMed:7774578}.
CC   -!- PTM: N-Glycosylated. {ECO:0000269|PubMed:9661882}.
CC   -!- PTM: Ubiquitinated; undergoes ubiquitination catalyzed by several E3
CC       ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results in the
CC       proteasomal and/or lysosomal degradation of the receptor thereby
CC       negatively regulating its activity. Deubiquitinated by USP15, leading
CC       to stabilization of the protein and enhanced TGF-beta signal. Its
CC       ubiquitination and proteasome-mediated degradation is negatively
CC       regulated by SDCBP (PubMed:25893292). {ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:22344298, ECO:0000269|PubMed:25893292}.
CC   -!- DISEASE: Loeys-Dietz syndrome 1 (LDS1) [MIM:609192]: An aortic aneurysm
CC       syndrome with widespread systemic involvement, characterized by
CC       arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or
CC       cleft palate. Physical findings include prominent joint laxity, easy
CC       bruising, wide and atrophic scars, velvety and translucent skin with
CC       easily visible veins, spontaneous rupture of the spleen or bowel, and
CC       catastrophic complications of pregnancy, including rupture of the
CC       gravid uterus and the arteries, either during pregnancy or in the
CC       immediate postpartum period. Some patients have craniosynostosis,
CC       exotropy, micrognathia and retrognathia, structural brain
CC       abnormalities, and intellectual deficit. {ECO:0000269|PubMed:15731757,
CC       ECO:0000269|PubMed:16596670, ECO:0000269|PubMed:16791849,
CC       ECO:0000269|PubMed:16928994, ECO:0000269|PubMed:19883511,
CC       ECO:0000269|PubMed:22113417}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. TGFBR1 mutation Gln-487
CC       has been reported to be associated with thoracic aortic aneurysms and
CC       dissection (TAAD) (PubMed:16791849). This phenotype, also known as
CC       thoracic aortic aneurysms type 5 (AAT5), is distinguised from LDS1 by
CC       having aneurysms restricted to thoracic aorta. It is unclear, however,
CC       if this condition is fulfilled in individuals bearing Gln-487 mutation,
CC       that is why they are considered as LDS1 by the OMIM resource.
CC       {ECO:0000269|PubMed:16791849}.
CC   -!- DISEASE: Multiple self-healing squamous epithelioma (MSSE)
CC       [MIM:132800]: A disorder characterized by multiple skin tumors that
CC       undergo spontaneous regression. Tumors appear most often on sun-exposed
CC       regions, are locally invasive, and undergo spontaneous resolution over
CC       a period of months leaving pitted scars. {ECO:0000269|PubMed:21358634}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- CAUTION: One report originally reported variant Ile-375
CC       (PubMed:22113417). This variant has been subsequently corrected to Arg-
CC       375 by the same authors (Ref.49). {ECO:0000269|PubMed:22113417,
CC       ECO:0000269|Ref.49}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L11695; AAA16073.1; -; mRNA.
DR   EMBL; AF054598; AAC08998.1; -; Genomic_DNA.
DR   EMBL; AF054590; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054591; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054592; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054593; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054594; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054595; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054596; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054597; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF035670; AAD02042.1; -; Genomic_DNA.
DR   EMBL; AF035662; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035663; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035664; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035665; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035666; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035667; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035668; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035669; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AY497473; AAR32097.1; -; Genomic_DNA.
DR   EMBL; AL162427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071181; AAH71181.1; -; mRNA.
DR   EMBL; AJ619019; CAF02096.2; -; mRNA.
DR   EMBL; AJ619020; CAF02097.1; -; mRNA.
DR   CCDS; CCDS47998.1; -. [P36897-3]
DR   CCDS; CCDS6738.1; -. [P36897-1]
DR   CCDS; CCDS78413.1; -. [P36897-2]
DR   PIR; A49432; A49432.
DR   RefSeq; NP_001124388.1; NM_001130916.2. [P36897-3]
DR   RefSeq; NP_001293139.1; NM_001306210.1. [P36897-2]
DR   RefSeq; NP_004603.1; NM_004612.3. [P36897-1]
DR   PDB; 1B6C; X-ray; 2.60 A; B/D/F/H=162-503.
DR   PDB; 1IAS; X-ray; 2.90 A; A/B/C/D/E=162-503.
DR   PDB; 1PY5; X-ray; 2.30 A; A=175-500.
DR   PDB; 1RW8; X-ray; 2.40 A; A=200-500.
DR   PDB; 1VJY; X-ray; 2.00 A; A=201-503.
DR   PDB; 2L5S; NMR; -; A=31-115.
DR   PDB; 2PJY; X-ray; 3.00 A; C=33-111.
DR   PDB; 2WOT; X-ray; 1.85 A; A=200-503.
DR   PDB; 2WOU; X-ray; 2.30 A; A=200-503.
DR   PDB; 2X7O; X-ray; 3.70 A; A/B/C/D/E=162-503.
DR   PDB; 3FAA; X-ray; 3.35 A; A/B/C/D/E=162-503.
DR   PDB; 3GXL; X-ray; 1.80 A; A=201-503.
DR   PDB; 3HMM; X-ray; 1.70 A; A=201-503.
DR   PDB; 3KCF; X-ray; 2.80 A; A/B/C/D/E=162-503.
DR   PDB; 3KFD; X-ray; 3.00 A; I/J/K/L=31-115.
DR   PDB; 3TZM; X-ray; 1.70 A; A=200-503.
DR   PDB; 4X0M; X-ray; 1.68 A; A=200-503.
DR   PDB; 4X2F; X-ray; 1.49 A; A=200-503.
DR   PDB; 4X2G; X-ray; 1.51 A; A=200-503.
DR   PDB; 4X2J; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2K; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2N; X-ray; 1.80 A; A=200-503.
DR   PDB; 5E8S; X-ray; 1.45 A; A=200-503.
DR   PDB; 5E8T; X-ray; 1.70 A; A=200-503.
DR   PDB; 5E8U; X-ray; 2.03 A; A=200-503.
DR   PDB; 5E8W; X-ray; 1.86 A; A=200-503.
DR   PDB; 5E8X; X-ray; 1.45 A; A=200-503.
DR   PDB; 5E8Z; X-ray; 1.51 A; A=200-503.
DR   PDB; 5E90; X-ray; 2.05 A; A=200-503.
DR   PDB; 5FRI; X-ray; 2.00 A; A=200-498.
DR   PDB; 5QIK; X-ray; 1.58 A; A=200-503.
DR   PDB; 5QIL; X-ray; 1.98 A; A=200-503.
DR   PDB; 5QIM; X-ray; 1.75 A; A=200-503.
DR   PDB; 5QTZ; X-ray; 1.83 A; A=200-503.
DR   PDB; 5QU0; X-ray; 1.67 A; A=200-503.
DR   PDB; 5USQ; X-ray; 2.55 A; A=200-498.
DR   PDB; 6B8Y; X-ray; 1.65 A; A=200-503.
DR   PDB; 6MAC; X-ray; 2.34 A; K=33-112.
DR   PDBsum; 1B6C; -.
DR   PDBsum; 1IAS; -.
DR   PDBsum; 1PY5; -.
DR   PDBsum; 1RW8; -.
DR   PDBsum; 1VJY; -.
DR   PDBsum; 2L5S; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 2WOT; -.
DR   PDBsum; 2WOU; -.
DR   PDBsum; 2X7O; -.
DR   PDBsum; 3FAA; -.
DR   PDBsum; 3GXL; -.
DR   PDBsum; 3HMM; -.
DR   PDBsum; 3KCF; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 3TZM; -.
DR   PDBsum; 4X0M; -.
DR   PDBsum; 4X2F; -.
DR   PDBsum; 4X2G; -.
DR   PDBsum; 4X2J; -.
DR   PDBsum; 4X2K; -.
DR   PDBsum; 4X2N; -.
DR   PDBsum; 5E8S; -.
DR   PDBsum; 5E8T; -.
DR   PDBsum; 5E8U; -.
DR   PDBsum; 5E8W; -.
DR   PDBsum; 5E8X; -.
DR   PDBsum; 5E8Z; -.
DR   PDBsum; 5E90; -.
DR   PDBsum; 5FRI; -.
DR   PDBsum; 5QIK; -.
DR   PDBsum; 5QIL; -.
DR   PDBsum; 5QIM; -.
DR   PDBsum; 5QTZ; -.
DR   PDBsum; 5QU0; -.
DR   PDBsum; 5USQ; -.
DR   PDBsum; 6B8Y; -.
DR   PDBsum; 6MAC; -.
DR   AlphaFoldDB; P36897; -.
DR   BMRB; P36897; -.
DR   SMR; P36897; -.
DR   BioGRID; 112904; 250.
DR   ComplexPortal; CPX-2544; TGF-beta-3-TGFR complex.
DR   ComplexPortal; CPX-529; TGF-beta-1-TGFR complex.
DR   ComplexPortal; CPX-834; TGF-beta-2-TGFR complex.
DR   CORUM; P36897; -.
DR   DIP; DIP-5935N; -.
DR   IntAct; P36897; 25.
DR   MINT; P36897; -.
DR   STRING; 9606.ENSP00000364133; -.
DR   BindingDB; P36897; -.
DR   ChEMBL; CHEMBL4439; -.
DR   DrugBank; DB07267; 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine.
DR   DrugBank; DB04480; 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole.
DR   DrugBank; DB03921; 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08450; N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine.
DR   DrugBank; DB07152; N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide.
DR   DrugBank; DB04434; Naphthyridine Inhibitor.
DR   DrugCentral; P36897; -.
DR   GuidetoPHARMACOLOGY; 1788; -.
DR   GlyGen; P36897; 1 site.
DR   iPTMnet; P36897; -.
DR   PhosphoSitePlus; P36897; -.
DR   BioMuta; TGFBR1; -.
DR   DMDM; 547777; -.
DR   EPD; P36897; -.
DR   jPOST; P36897; -.
DR   MassIVE; P36897; -.
DR   MaxQB; P36897; -.
DR   PaxDb; P36897; -.
DR   PeptideAtlas; P36897; -.
DR   PRIDE; P36897; -.
DR   ProteomicsDB; 55234; -. [P36897-1]
DR   ProteomicsDB; 55235; -. [P36897-2]
DR   ProteomicsDB; 55236; -. [P36897-3]
DR   Antibodypedia; 29038; 620 antibodies from 42 providers.
DR   DNASU; 7046; -.
DR   Ensembl; ENST00000374990.6; ENSP00000364129.2; ENSG00000106799.13. [P36897-3]
DR   Ensembl; ENST00000374994.9; ENSP00000364133.4; ENSG00000106799.13. [P36897-1]
DR   Ensembl; ENST00000552516.5; ENSP00000447297.1; ENSG00000106799.13. [P36897-2]
DR   GeneID; 7046; -.
DR   KEGG; hsa:7046; -.
DR   MANE-Select; ENST00000374994.9; ENSP00000364133.4; NM_004612.4; NP_004603.1.
DR   UCSC; uc004azd.4; human. [P36897-1]
DR   CTD; 7046; -.
DR   DisGeNET; 7046; -.
DR   GeneCards; TGFBR1; -.
DR   GeneReviews; TGFBR1; -.
DR   HGNC; HGNC:11772; TGFBR1.
DR   HPA; ENSG00000106799; Low tissue specificity.
DR   MalaCards; TGFBR1; -.
DR   MIM; 132800; phenotype.
DR   MIM; 190181; gene.
DR   MIM; 609192; phenotype.
DR   neXtProt; NX_P36897; -.
DR   OpenTargets; ENSG00000106799; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 60030; Loeys-Dietz syndrome.
DR   Orphanet; 65748; Multiple self-healing squamous epithelioma.
DR   PharmGKB; PA36485; -.
DR   VEuPathDB; HostDB:ENSG00000106799; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   GeneTree; ENSGT00940000156394; -.
DR   HOGENOM; CLU_000288_8_1_1; -.
DR   InParanoid; P36897; -.
DR   OMA; EMINMNH; -.
DR   PhylomeDB; P36897; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   PathwayCommons; P36897; -.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; P36897; -.
DR   SIGNOR; P36897; -.
DR   BioGRID-ORCS; 7046; 51 hits in 1097 CRISPR screens.
DR   ChiTaRS; TGFBR1; human.
DR   EvolutionaryTrace; P36897; -.
DR   GeneWiki; TGF_beta_receptor_1; -.
DR   GenomeRNAi; 7046; -.
DR   Pharos; P36897; Tchem.
DR   PRO; PR:P36897; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P36897; protein.
DR   Bgee; ENSG00000106799; Expressed in saphenous vein and 189 other tissues.
DR   ExpressionAtlas; P36897; baseline and differential.
DR   Genevisible; P36897; HS.
DR   GO; GO:0048179; C:activin receptor complex; IBA:GO_Central.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:AgBase.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0070021; C:transforming growth factor beta ligand-receptor complex; IPI:ComplexPortal.
DR   GO; GO:0048185; F:activin binding; IBA:GO_Central.
DR   GO; GO:0016361; F:activin receptor activity, type I; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:HGNC-UCL.
DR   GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:BHF-UCL.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0032924; P:activin receptor signaling pathway; ISS:AgBase.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001824; P:blastocyst development; IEA:Ensembl.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0048870; P:cell motility; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042118; P:endothelial cell activation; ISS:AgBase.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:1905223; P:epicardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043062; P:extracellular structure organization; TAS:UniProtKB.
DR   GO; GO:0046847; P:filopodium assembly; IEA:Ensembl.
DR   GO; GO:0008354; P:germ cell migration; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:AgBase.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:AgBase.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:AgBase.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:BHF-UCL.
DR   GO; GO:0060017; P:parathyroid gland development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:BHF-UCL.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:HGNC-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:AgBase.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:BHF-UCL.
DR   GO; GO:1905075; P:positive regulation of tight junction disassembly; ISS:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:HGNC-UCL.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:AgBase.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0060021; P:roof of mouth development; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC-UCL.
DR   GO; GO:0001501; P:skeletal system development; ISS:BHF-UCL.
DR   GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048538; P:thymus development; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; TAS:UniProtKB.
DR   Gene3D; 2.10.60.10; -; 1.
DR   IDEAL; IID00413; -.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis;
KW   ATP-binding; Cell junction; Cell membrane; Craniosynostosis;
KW   Differentiation; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Glycoprotein; Growth regulation; Isopeptide bond; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Tight junction; Transferase;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000269|PubMed:9661882"
FT   CHAIN           34..503
FT                   /note="TGF-beta receptor type-1"
FT                   /id="PRO_0000024423"
FT   TOPO_DOM        34..126
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        127..147
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        148..503
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          175..204
FT                   /note="GS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00585"
FT   DOMAIN          205..495
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOTIF           193..194
FT                   /note="FKBP1A-binding"
FT   ACT_SITE        333
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         211..219
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         232
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         185
FT                   /note="Phosphothreonine; by TGFBR2"
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MOD_RES         186
FT                   /note="Phosphothreonine; by TGFBR2"
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MOD_RES         187
FT                   /note="Phosphoserine; by TGFBR2"
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MOD_RES         189
FT                   /note="Phosphoserine; by TGFBR2"
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MOD_RES         191
FT                   /note="Phosphoserine; by TGFBR2"
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..54
FT                   /evidence="ECO:0000269|PubMed:18243111,
FT                   ECO:0000269|PubMed:20207738"
FT   DISULFID        38..41
FT                   /evidence="ECO:0000269|PubMed:18243111,
FT                   ECO:0000269|PubMed:20207738"
FT   DISULFID        48..71
FT                   /evidence="ECO:0000269|PubMed:18243111,
FT                   ECO:0000269|PubMed:20207738"
FT   DISULFID        86..100
FT                   /evidence="ECO:0000269|PubMed:18243111,
FT                   ECO:0000269|PubMed:20207738"
FT   DISULFID        101..106
FT                   /evidence="ECO:0000269|PubMed:18243111,
FT                   ECO:0000269|PubMed:20207738"
FT   CROSSLNK        391
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         114
FT                   /note="T -> TGPFS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17845732"
FT                   /id="VSP_041326"
FT   VAR_SEQ         115..191
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041327"
FT   VARIANT         24..26
FT                   /note="Missing (in allele TGFBR1*6A; could be a tumor
FT                   susceptibility allele)"
FT                   /id="VAR_022342"
FT   VARIANT         26
FT                   /note="A -> AA (in allele TGFBR1*10A)"
FT                   /evidence="ECO:0000269|PubMed:9661882"
FT                   /id="VAR_022343"
FT   VARIANT         41
FT                   /note="C -> Y (in MSSE; hypomorphic variant)"
FT                   /evidence="ECO:0000269|PubMed:21358634"
FT                   /id="VAR_065826"
FT   VARIANT         45
FT                   /note="N -> S (in MSSE; hypomorphic variant;
FT                   dbSNP:rs387906696)"
FT                   /evidence="ECO:0000269|PubMed:21358634"
FT                   /id="VAR_065827"
FT   VARIANT         52
FT                   /note="G -> R (in MSSE; hypomorphic variant;
FT                   dbSNP:rs587776865)"
FT                   /evidence="ECO:0000269|PubMed:21358634"
FT                   /id="VAR_065828"
FT   VARIANT         83
FT                   /note="P -> L (in MSSE; hypomorphic variant;
FT                   dbSNP:rs757374917)"
FT                   /evidence="ECO:0000269|PubMed:21358634"
FT                   /id="VAR_065829"
FT   VARIANT         139
FT                   /note="I -> V (in dbSNP:rs148176750)"
FT                   /evidence="ECO:0000269|PubMed:18987736"
FT                   /id="VAR_054160"
FT   VARIANT         153
FT                   /note="V -> I (in dbSNP:rs56014374)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041412"
FT   VARIANT         200
FT                   /note="T -> I (in LDS1; dbSNP:rs121918712)"
FT                   /evidence="ECO:0000269|PubMed:15731757"
FT                   /id="VAR_022344"
FT   VARIANT         232
FT                   /note="K -> E (in LDS1)"
FT                   /evidence="ECO:0000269|PubMed:16928994"
FT                   /id="VAR_029481"
FT   VARIANT         241
FT                   /note="S -> L (in LDS1; dbSNP:rs111854391)"
FT                   /evidence="ECO:0000269|PubMed:16596670,
FT                   ECO:0000269|PubMed:16791849"
FT                   /id="VAR_029482"
FT   VARIANT         266
FT                   /note="D -> Y (in LDS1)"
FT                   /evidence="ECO:0000269|PubMed:22113417"
FT                   /id="VAR_066720"
FT   VARIANT         267
FT                   /note="N -> H (in a patient with Marfan syndrome)"
FT                   /evidence="ECO:0000269|PubMed:16791849"
FT                   /id="VAR_029483"
FT   VARIANT         291
FT                   /note="Y -> C (in dbSNP:rs35974499)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041413"
FT   VARIANT         318
FT                   /note="M -> R (in LDS1; dbSNP:rs121918710)"
FT                   /evidence="ECO:0000269|PubMed:15731757"
FT                   /id="VAR_022345"
FT   VARIANT         351
FT                   /note="D -> G (in LDS1)"
FT                   /evidence="ECO:0000269|PubMed:19883511"
FT                   /id="VAR_066721"
FT   VARIANT         375
FT                   /note="T -> R (in LDS1)"
FT                   /evidence="ECO:0000269|PubMed:22113417"
FT                   /id="VAR_066722"
FT   VARIANT         400
FT                   /note="D -> G (in LDS1; dbSNP:rs121918711)"
FT                   /evidence="ECO:0000269|PubMed:15731757"
FT                   /id="VAR_022346"
FT   VARIANT         487
FT                   /note="R -> P (in LDS1; dbSNP:rs113605875)"
FT                   /evidence="ECO:0000269|PubMed:15731757,
FT                   ECO:0000269|PubMed:16928994"
FT                   /id="VAR_022347"
FT   VARIANT         487
FT                   /note="R -> Q (in LDS1; dbSNP:rs113605875)"
FT                   /evidence="ECO:0000269|PubMed:16791849,
FT                   ECO:0000269|PubMed:16928994, ECO:0000269|PubMed:22113417"
FT                   /id="VAR_029484"
FT   VARIANT         487
FT                   /note="R -> W (in LDS1; dbSNP:rs111426349)"
FT                   /evidence="ECO:0000269|PubMed:16928994"
FT                   /id="VAR_029485"
FT   MUTAGEN         185..186
FT                   /note="TT->VV: Loss of phosphorylation on threonine
FT                   residues. Loss of threonine phosphorylation, reduced
FT                   phosphorylation on serine residues and loss of response to
FT                   TGF-beta; when associated with A-187; A-189 and A-191."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         187
FT                   /note="S->A: Loss of threonine phosphorylation, reduced
FT                   phosphorylation on serine residues and loss of response to
FT                   TGF-beta; when associated with 185-VV-186; A-189 and
FT                   A-191."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         189
FT                   /note="S->A: Loss of threonine phosphorylation, reduced
FT                   phosphorylation on serine residues and loss of response to
FT                   TGF-beta; when associated with 185-VV-186; A-187 and
FT                   A-191."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         191
FT                   /note="S->A: Loss of threonine phosphorylation, reduced
FT                   phosphorylation on serine residues and loss of response to
FT                   TGF-beta; when associated with 185-VV-186; A-187 and
FT                   A-189."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         193
FT                   /note="L->G: Loss of interaction with FKBP1A."
FT                   /evidence="ECO:0000269|PubMed:9233797"
FT   MUTAGEN         194
FT                   /note="P->K: Loss of interaction with FKBP1A."
FT                   /evidence="ECO:0000269|PubMed:9233797"
FT   MUTAGEN         200
FT                   /note="T->D: Loss of response to TGF-beta."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         200
FT                   /note="T->V: Loss of phosphorylation. Loss of response to
FT                   TGF-beta."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         204
FT                   /note="T->D: Constitutive activation."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   MUTAGEN         204
FT                   /note="T->V: Reduced phosphorylation. Reduced response to
FT                   TGF-beta."
FT                   /evidence="ECO:0000269|PubMed:7774578"
FT   STRAND          35..37
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   TURN            42..46
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          47..49
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          51..63
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          65..72
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   HELIX           74..76
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   TURN            84..86
FT                   /evidence="ECO:0007829|PDB:3KFD"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          94..101
FT                   /evidence="ECO:0007829|PDB:6MAC"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:3KFD"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:2L5S"
FT   HELIX           177..183
FT                   /evidence="ECO:0007829|PDB:1B6C"
FT   STRAND          187..190
FT                   /evidence="ECO:0007829|PDB:3KCF"
FT   STRAND          191..193
FT                   /evidence="ECO:0007829|PDB:1B6C"
FT   HELIX           202..204
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          205..213
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          215..224
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          227..234
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           236..238
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           239..249
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          251..253
FT                   /evidence="ECO:0007829|PDB:3KCF"
FT   STRAND          262..269
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          271..281
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           288..294
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           299..317
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:5E8X"
FT   STRAND          328..330
FT                   /evidence="ECO:0007829|PDB:5E8Z"
FT   HELIX           336..338
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          339..341
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          347..349
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          356..359
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   TURN            360..363
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          364..367
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          368..371
FT                   /evidence="ECO:0007829|PDB:5E8X"
FT   HELIX           376..378
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           381..384
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           393..413
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   STRAND          417..419
FT                   /evidence="ECO:0007829|PDB:3KCF"
FT   TURN            427..431
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           438..445
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           456..460
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           462..474
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           479..481
FT                   /evidence="ECO:0007829|PDB:5E8S"
FT   HELIX           485..497
FT                   /evidence="ECO:0007829|PDB:5E8S"
SQ   SEQUENCE   503 AA;  55960 MW;  179F11404725DDCB CRC64;
     MEAAVAAPRP RLLLLVLAAA AAAAAALLPG ATALQCFCHL CTKDNFTCVT DGLCFVSVTE
     TTDKVIHNSM CIAEIDLIPR DRPFVCAPSS KTGSVTTTYC CNQDHCNKIE LPTTVKSSPG
     LGPVELAAVI AGPVCFVCIS LMLMVYICHN RTVIHHRVPN EEDPSLDRPF ISEGTTLKDL
     IYDMTTSGSG SGLPLLVQRT IARTIVLQES IGKGRFGEVW RGKWRGEEVA VKIFSSREER
     SWFREAEIYQ TVMLRHENIL GFIAADNKDN GTWTQLWLVS DYHEHGSLFD YLNRYTVTVE
     GMIKLALSTA SGLAHLHMEI VGTQGKPAIA HRDLKSKNIL VKKNGTCCIA DLGLAVRHDS
     ATDTIDIAPN HRVGTKRYMA PEVLDDSINM KHFESFKRAD IYAMGLVFWE IARRCSIGGI
     HEDYQLPYYD LVPSDPSVEE MRKVVCEQKL RPNIPNRWQS CEALRVMAKI MRECWYANGA
     ARLTALRIKK TLSQLSQQEG IKM
//
